Biotech Values

[oc631]

This is not a question of Teva’s wanting to be honest with investors, but rather that MNTA’s lawsuit against Teva is now serving the business purpose

I've come to look at the lawsuit/offering as a single event. The lawsuit appeared to be a contingency for institutional investors to participate in the offering. I'm still not happy about about the price/timing of the offering but I do feel better about MNTA when looking at the lawsuit from this context.